Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

R.L. Coleman, A.M. Oza, D. Lorusso, C. Aghajanian, A. Oaknin, A. Dean, N. Colombo, J.I. Weberpals, A. Clamp, G. Scambia, A. Leary, R.W. Holloway, M.A. Gancedo, P.C. Fong, J.C. Goh, D.M. O'Malley, D.K. Armstrong, J. Garcia-Donas, E.M. Swisher, A. FloquetG.E. Konecny, I.A. McNeish, C.L. Scott, T. Cameron, L. Maloney, J. Isaacson, S. Goble, C. Grace, T.C. Harding, M. Raponi, J. Sun, K.K. Lin, H. Giordano, J.A. Ledermann

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)1949-1961
Number of pages13
JournalThe Lancet
Volume390
Issue number10106
DOIs
Publication statusPublished - 2017

Cite this

Coleman, R. L., Oza, A. M., Lorusso, D., Aghajanian, C., Oaknin, A., Dean, A., Colombo, N., Weberpals, J. I., Clamp, A., Scambia, G., Leary, A., Holloway, R. W., Gancedo, M. A., Fong, P. C., Goh, J. C., O'Malley, D. M., Armstrong, D. K., Garcia-Donas, J., Swisher, E. M., ... Ledermann, J. A. (2017). Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 390(10106), 1949-1961. https://doi.org/10.1016/S0140-6736(17)32440-6